ECSP16095557A - Métodos para tratar infecciones - Google Patents

Métodos para tratar infecciones

Info

Publication number
ECSP16095557A
ECSP16095557A ECIEPI201695557A ECPI201695557A ECSP16095557A EC SP16095557 A ECSP16095557 A EC SP16095557A EC IEPI201695557 A ECIEPI201695557 A EC IEPI201695557A EC PI201695557 A ECPI201695557 A EC PI201695557A EC SP16095557 A ECSP16095557 A EC SP16095557A
Authority
EC
Ecuador
Prior art keywords
methods
treat infections
days
treating
approximately
Prior art date
Application number
ECIEPI201695557A
Other languages
English (en)
Inventor
Jarrod Longcor
Scott Hopkins
Danping Li
Original Assignee
Ferretti Antonio C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54868662&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP16095557(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferretti Antonio C filed Critical Ferretti Antonio C
Publication of ECSP16095557A publication Critical patent/ECSP16095557A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

La presente invención se refiere a métodos para tratar, prevenir, o reducir el de infecciones microbianas al mismo tiempo que minimiza los efectos adversos gastrointestinales usando un régimen de dosificación de dos etapas que comprende aproximadamente 1 hasta aproximadamente 7 días de administración intravenosa seguido por aproximadamente 1 hasta aproximadamente 14 días de administración oral de un agente antimicrobiano.
ECIEPI201695557A 2014-06-20 2016-12-20 Métodos para tratar infecciones ECSP16095557A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462014790P 2014-06-20 2014-06-20
US201462034468P 2014-08-07 2014-08-07

Publications (1)

Publication Number Publication Date
ECSP16095557A true ECSP16095557A (es) 2017-03-31

Family

ID=54868662

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201695557A ECSP16095557A (es) 2014-06-20 2016-12-20 Métodos para tratar infecciones

Country Status (17)

Country Link
US (2) US20150366858A1 (es)
EP (1) EP3157633A4 (es)
JP (1) JP2017518354A (es)
CN (1) CN106687179A (es)
AU (1) AU2015276911A1 (es)
BR (1) BR112016029896A2 (es)
CA (1) CA2952955A1 (es)
CL (1) CL2016003271A1 (es)
EA (1) EA201692531A1 (es)
EC (1) ECSP16095557A (es)
IL (1) IL249616A0 (es)
MX (1) MX2016017348A (es)
PH (1) PH12016502547A1 (es)
SV (1) SV2016005348A (es)
TW (1) TW201605447A (es)
UY (1) UY36183A (es)
WO (1) WO2015196076A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693695A (zh) * 2014-11-24 2016-06-22 重庆医药工业研究院有限责任公司 一种德拉沙星葡甲胺盐的晶型及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814256A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Feste, schnellzerfallende Cetirizin-Formulierungen
DK3056492T3 (da) * 2004-10-08 2021-12-13 Abbvie Inc Megluminsalt og krystallinke former deraf af et lægemiddel (delafloxacin)
ES2384333T3 (es) * 2005-04-11 2012-07-03 Abbott Laboratories Composiciones farmacéuticas que tienen perfiles de disolución mejorados para fármacos poco solubles
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
CN1943561A (zh) * 2006-08-23 2007-04-11 北京阜康仁生物制药科技有限公司 普卢利沙星口腔崩解片及其制备方法
PL3766876T3 (pl) * 2008-09-24 2024-04-02 Melinta Subsidiary Corp. Preparat farmaceutyczny zawierający pochodną chinolonu
AU2009314072C1 (en) * 2008-11-15 2016-11-10 Melinta Subsidiary Corp. Antimicrobial compositions
WO2010096551A2 (en) * 2009-02-18 2010-08-26 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions
KR102237887B1 (ko) * 2013-03-15 2021-04-07 멜린타 서브시디어리 코프. 항생제를 사용하여 과체중 및 비만 환자에서 감염을 치료하는 방법

Also Published As

Publication number Publication date
CL2016003271A1 (es) 2017-08-04
CA2952955A1 (en) 2015-12-23
SV2016005348A (es) 2017-03-02
MX2016017348A (es) 2017-04-06
TW201605447A (zh) 2016-02-16
EP3157633A4 (en) 2018-02-21
BR112016029896A2 (pt) 2017-08-22
AU2015276911A1 (en) 2017-01-12
PH12016502547A1 (en) 2017-04-10
US20150366858A1 (en) 2015-12-24
JP2017518354A (ja) 2017-07-06
CN106687179A (zh) 2017-05-17
US20170368055A1 (en) 2017-12-28
IL249616A0 (en) 2017-02-28
UY36183A (es) 2016-01-29
EA201692531A1 (ru) 2017-05-31
AU2015276911A2 (en) 2018-04-26
WO2015196076A1 (en) 2015-12-23
EP3157633A1 (en) 2017-04-26

Similar Documents

Publication Publication Date Title
JOP20160092B1 (ar) علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية
MX2018006503A (es) Compuesto novedoso de bifenilo o una sal del mismo.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
MX2019014104A (es) Compuesto novedoso de bifenilo o sal del mismo.
MX2016009337A (es) Derivados de azepano y metodos para tratar infecciones por hepatitis b.
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
MX381776B (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
EA201692493A1 (ru) Противомикробные фармацевтические композиции со способностями ингибирования множественной лекарственной устойчивости
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
ECSP16095557A (es) Métodos para tratar infecciones
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX2019000006A (es) Composiciones para el tratamiento de estrias y ulceras de origen isquemico.
CR20160591A (es) Metodos para tratar infecciones